Yu Wang1, Liyan Yu2, Nan Fang3, Bing Sun4. 1. Department of Thoracic Surgery, the Second Affiliated Hospital of Dalian Medical University, Liaoning 116023, China. 2. Department of Respiratory Medicine, the First Affiliated Hospital of Dalian Medical University, Liaoning 116011, China. 3. Beijing USCI Medical Laboratory Co., Ltd , 100195, China. 4. Department of Thoracic Surgery, the First Affiliated Hospital of Dalian Medical University, Liaoning 116011, China. Email: dysunbing@163.com.
Abstract
OBJECTIVE: To provide mutational analysis and targeted therapy for Chinese patients with non-small cell lung cancer (NSCLCs). METHODS: Mutation of 13 genes including EGFR, ALK, KRAS were detected among 102 patients with NSCLCs by next-generation sequencing, and the correlation between mutations and clinical characteristics and response to targeted therapy was analyzed. RESULTS: In total 42 EGFR mutations (40.8%), 3 ALK fusions (3.9%), 6 KRAS mutations (5.8%), 3 PIK3CA mutations and amplifications (2.9%), 1 MET exon 14-skipping (1%) and 1 RET fusion (1%) were detected. The occurrence of mutations have varied with sample types and pathological types. Seventeen out of 20 EGFR tyrosine kinase inhibitor (TKI)-treated patients with EGFR mutations have shown remission. CONCLUSION: The mutational frequency of NSCLCs among Chinese patients slightly differed from the western populations, in particular the frequency of ALK fusion. The mutations have well correlated with clinical response to targeted therapy.
OBJECTIVE: To provide mutational analysis and targeted therapy for Chinese patients with non-small cell lung cancer (NSCLCs). METHODS: Mutation of 13 genes including EGFR, ALK, KRAS were detected among 102 patients with NSCLCs by next-generation sequencing, and the correlation between mutations and clinical characteristics and response to targeted therapy was analyzed. RESULTS: In total 42 EGFR mutations (40.8%), 3 ALK fusions (3.9%), 6 KRAS mutations (5.8%), 3 PIK3CA mutations and amplifications (2.9%), 1 MET exon 14-skipping (1%) and 1 RET fusion (1%) were detected. The occurrence of mutations have varied with sample types and pathological types. Seventeen out of 20 EGFR tyrosine kinase inhibitor (TKI)-treated patients with EGFR mutations have shown remission. CONCLUSION: The mutational frequency of NSCLCs among Chinese patients slightly differed from the western populations, in particular the frequency of ALK fusion. The mutations have well correlated with clinical response to targeted therapy.